Göm menyn

Publications for Per Rosenberg


Co-author map based on Web of Sciences articles 2007-

Publications mentioned in social media 300 times*

Journal Articles

Per Rosenberg, Preben Kjölhede, Christian Staf, Maria Bjurberg, Christer Borgfeldt, Pernilla Dahm-Kahler, Kristina Hellman, Elisabet Hjerpe, Erik Holmberg, Karin Stalberg, Bengt Tholander, Elisabeth Åvall Lundqvist and Thomas Hogberg
  Data quality in the Swedish Quality Register of Gynecologic Cancer - a Swedish Gynecologic Cancer Group (SweGCG) study
  Acta Oncologica, 2018, 57(3), 346-353.
 Web of Science® Times Cited: 1

Elisabet Hjerpe, Christian Staf, Pernilla Dahm-Kahler, Karin Stalberg, Maria Bjurberg, Erik Holmberg, Christer Borgfeldt, Bengt Tholander, Kristina Hellman, Preben Kjölhede, Thomas Högberg, Per Rosenberg and Elisabeth Åvall Lundqvist
  Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) study
  Acta Oncologica, 2018, 57(3), 331-337.

Kristina Lindemann, Emma Gibbs, Elisabeth Åvall-Lundqvist, Rene dePont Christensen, Kathrine Woie, Marten Kalling, Annika Auranen, Seija Grenman, Thomas Hoegberg, Per Rosenberg, Tone Skeie-Jensen, Elisabet Hjerpe, Anne Dorum, Val Gebski and Gunnar Kristensen
  Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
  British Journal of Cancer, 2017, 116(4), 455-463.
 Web of Science® Times Cited: 1

Pernilla Dahm-Kähler, Christer Borgfeldt, Erik Holmberg, Christian Staf, Henrik Falconer, Maria Bjurberg, Preben Kjölhede, Per Rosenberg, Karin Stålberg, Thomas Högberg and Elisabeth Åvall-Lundqvist
  Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).
  Gynecologic Oncology, 2017, 144(1), 167-173.
 Web of Science® Times Cited: 1

Karin Stålberg, Preben Kjölhede, M. Bjurberg, C. Borgfeldt, P. Dahm-Kahler, H. Falconer, E. Holmberg, C. Staf, B. Tholander, Elisabeth Åvall-Lundqvist, Per Rosenberg and T. Högberg
  Risk factors for lymph node metastases in women with endometrial cancer: A population-based, nation-wide register studyOn behalf of the Swedish Gynecological Cancer Group
  International Journal of Cancer, 2017, 140(12), 2693-2700.
 Web of Science® Times Cited: 2

M. R. Mirza, B. J. Monk, J. Herrstedt, A. M. Oza, S. Mahner, A. Redondo, M. Fabbro, J. A. Ledermann, D. Lorusso, I. Vergote, N. E. Ben-Baruch, C. Marth, R. Madry, R. D. Christensen, J. S. Berek, A. Dorum, A. V. Tinker, A. du Bois, A. Gonzalez-Martin, P. Follana, B. Benigno, Per Rosenberg, L. Gilbert, B. J. Rimel, J. Buscema, J. P. Balser, S. Agarwal and U. A. Matulonis
  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
  New England Journal of Medicine, 2016, 375(22), 2154-2164.
   Fulltext  PDF  
 Web of Science® Times Cited: 171

Jalid Sehouli, Klaus Pietzner, Pauline Wimberger, Ignace Vergote, Per Rosenberg, Andreas Schneeweiss, Carsten Bokemeyer, Christoph Salat, Giovanni Scambia, Dominique Berton-Rigaud, Armando Santoro, Andres Cervantes, Olivier Tredan, Christophe Tournigand, Nicoletta Colombo, Alexander S. Dudnichenko, Anneke Westermann, Hilke Friccius-Quecke and Florian Lordick
  Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study
  Medical Oncology, 2014, 31(8), 76.
 Web of Science® Times Cited: 5

Anne von Heideman, Bengt Tholander, Birgitta Grundmark, Stefan Cajander, Eva Gerdin, Leif Holm, Agneta Axelsson, Per Rosenberg, Haile Mahteme, Erika Daniel, Rolf Larsson and Peter Nygren
  Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome
  Acta Oncologica, 2014, 53(2), 242-250.
 Web of Science® Times Cited: 1

Kristina Lindemann, Susanne Malander, Rene D. Christensen, Mansoor R. Mirza, Gunnar B. Kristensen, Elisabeth Åvall-Lundqvist, Ignace Vergote, Per Rosenberg, Karin Boman and Britta Nordstrom
  Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
  BMC Cancer, 2014, 14(68), .
   Fulltext  PDF  
 Web of Science® Times Cited: 12

Klaus Pietzner, Ignace Vergote, Armando Santoro, Radoslav Chekerov, Frederik Marme, Per Rosenberg, Holger Martinius, Hilke Friccius-Quecke and Jalid Sehouli
  Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study
  Medical Oncology, 2014, 31(12), 308.
 Web of Science® Times Cited: 3

Henrik Green, Peter Söderkvist, Per Rosenberg, Rajaa A Mirghani, Per Rymark, Elisabeth Åvall Lundqvist and Curt Peterson
  Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer
  Basic & Clinical Pharmacology & Toxicology, 2009, 104(2), 130-137.
   Fulltext  PDF  
 Web of Science® Times Cited: 76

Henrik Green, Peter Söderkvist, Per Rosenberg, Grörgy Horvath and Curt Peterson
  ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel
  Journal of Pharmaceutical Sciences, 2008, 97(6), 2045-2048.
   Fulltext  PDF  
 Web of Science® Times Cited: 38

B. Sorbe, H. Andersson, K. Boman, Per Rosenberg and M. Kalling
  Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel - Long-term follow-up
  International Journal of Gynecological Cancer, 2008, 18(4), 803-808.
 Web of Science® Times Cited: 39

Henrik Green, Peter Söderkvist, Per Rosenberg, Rajaa A. Mirghani, Per Rymark, Elisabeth Åvall-Lundqvist and Curt Peterson
  Pharmacogenetics of Paclitaxel in the Treatment of Ovarian Cancer – a Pilot Study in Preparation of Individualized Chemotherapy
  Clinical Cancer Research, 2007, , .

Henrik Green, Peter Söderkvist, Per Rosenberg, Horvath György and Curt Peterson
  Letters to the Editor: ABCB1 2677>T/A Genotype and paclitaxel pharmacogenetics in ovarian cancer - Response
  Clinical Cancer Research, 2006, 12(13), 4127-4129.
 Web of Science® Times Cited: 2

Henrik Green, Peter Söderkvist, Per Rosenberg, György Horvath and Curt Peterson
  mdr-1 single nucleotide polymorphisms in ovarian cancer tissue – G2677T/A correlates with response to paclitaxel chemotherapy
  Clinical Cancer Research, 2006, 12(3 pt 1), 854-859.
   Fulltext  PDF  
 Web of Science® Times Cited: 122

Henrik Green, Per Rosenberg, Peter Söderkvist, György Horvath and Curt Peterson
  β-tubulin mutations in ovarian cancer using single strand conformation analysis – risk of false positive results from paraffin embedded tissues
  Cancer Letters, 2006, 236(1), 148-154.
   Fulltext  PDF  
 Web of Science® Times Cited: 7

Ph.D. Theses

Henrik Green
  Pharmacogenetic Studies of Paclitaxel in Ovarian Cancer: focus on interindividual differences in pharmacodynamics and pharmacokinetics
  2007.


  Fulltext PDF

* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.

 



Responsible for this page: Peter Berkesand
Last updated: 2017-02-21